Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
President Luiz Inácio Lula da Silva, 80, was discharged from a Brasília eye hospital on Friday after a successful cataract operation. The veteran leftist leader is recovering at a presidential retreat and is scheduled to return to work on Monday, amid a busy domestic and international agenda.
